

**UNITED STATES SECURITIES AND EXCHANGE
COMMISSION**

Washington, D.C. 20549

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF
SECURITIES**

OMB APPROVAL

OMB Number: 3235-0104

Estimated average burden

hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Perrin Steven</u> (Last) (First) (Middle) <u>C/O NOVUS THERAPEUTICS, INC.</u> <u>19900 MACARTHUR BLVD.,</u> <u>SUITE 550</u> (Street) <u>IRVINE CA 92612</u> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>09/14/2020</u>	3. Issuer Name and Ticker or Trading Symbol <u>Novus Therapeutics, Inc. [NVUS]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <p align="center"><u>See Remarks</u></p>	5. If Amendment, Date of Original Filed (Month/Day/Year)
		6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person	

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
---------------------------------	---	--	---

**Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Stock Option (Right to Buy)	(1)	09/14/2030	Series X1 Convertible Preferred Stock ⁽²⁾	7,856.409	500	D	
Stock Option (Right to Buy)	(3)	01/28/2030	Series X1 Convertible Preferred Stock ⁽²⁾	2,078.859	495	D	
Stock Option (Right to Buy)	(3)	01/28/2030	Common Stock	48,896	0.495	D	
Stock Option (Right to Buy)	(3)	01/28/2030	Series X1 Convertible Preferred Stock ⁽²⁾	2,514.285	495	D	
Stock Option (Right to Buy)	(3)	01/28/2030	Common Stock	56,719	0.495	D	
Stock Option (Right to Buy)	(3)	09/07/2030	Series X1 Convertible Preferred Stock ⁽²⁾	10,672.926	380.8	D	
Stock Option (Right to Buy)	(3)	09/07/2030	Common Stock	240,767	0.3808	D	
Stock Option (Right to Buy)	(4)	01/28/2030	Series X1 Convertible Preferred Stock ⁽²⁾	432.257	495	D	
Stock Option (Right to Buy)	(4)	01/28/2030	Common Stock	9,751	0.495	D	
Stock Option (Right to Buy)	(4)	01/28/2030	Series X1 Convertible Preferred Stock ⁽²⁾	656.165	495	D	
Stock Option (Right to Buy)	(4)	01/28/2030	Common Stock	14,802	0.495	D	

POWER OF ATTORNEY

Know all by these presents, that the undersigned hereby constitutes and appoints Jon Kuwahara and Ryan A. Murr, with full power of substitution, the undersigned's true and lawful attorney-in-fact to:

- (1) prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the U.S. Securities and Exchange Commission (the "SEC") a Form ID, including amendments thereto, and any other documents necessary or appropriate to obtain codes, passwords and passphrases enabling the undersigned to make electronic filings with the SEC of reports required by the Securities Exchange Act of 1934 or any rule or regulation of the SEC;
- (2) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of Novus Therapeutics, Inc. (the "Company"), Forms 3, 4, and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;
- (3) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5, complete and execute any amendment or amendments thereto, and timely file such form with the SEC and any securities exchange or similar authority; and
- (4) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned also ratifies hereby any action previously taken by each attorney-in-fact that would have been authorized by this power of attorney if it has been in effect at the time such action was taken. The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of the undersigned, is not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934, as amended.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorney-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 16th day of September 2020.

/s/ Steven Perrin

Signature

Steven Perrin

Print Name

